Introduction
============

Notable developments have been made in the systemic therapy and early diagnosis of breast cancer; however, this disease remains to be the second leading cause of cancer-associated mortality in females ([@b1-mmr-20-05-4045],[@b2-mmr-20-05-4045]). Distant metastasis represents as the major cause of mortality in patients with breast cancer ([@b3-mmr-20-05-4045]). Metastasis is a multistep process characterized by the progressive accumulation of genetic alterations that results in aberrant cell growth, malignant transformation, vascular invasion and ultimately, metastasis ([@b4-mmr-20-05-4045]--[@b5-mmr-20-05-4045]). Gene expression and proteomics analyses have revealed several novel metastasis-associated factors underlying the development and progression of breast cancer ([@b6-mmr-20-05-4045]--[@b11-mmr-20-05-4045]); however, the role of these factors requires further investigation, yet metastasis remains a serious problem in the treatment of this disease.

Transgelin 2 (TAGLN2) is a 22-kDa protein and one of the earliest markers of differentiated smooth muscle ([@b12-mmr-20-05-4045]). TAGLN2 belongs to the calponin family of proteins as it contains an N-terminal calponin homology domain and a C-terminal calponin-like domain ([@b13-mmr-20-05-4045]). TAGLN2 binds to actin to facilitate the formation of cytoskeletal structures, such as stress fibers ([@b14-mmr-20-05-4045]). The dysregulated expression of TAGLN2 has been observed in various types of cancer ([@b7-mmr-20-05-4045],[@b15-mmr-20-05-4045]--[@b18-mmr-20-05-4045]). A previous study indicated that TAGLN2 inhibited the motility of hepatocarcinoma cells by suppressing actin polymerization ([@b16-mmr-20-05-4045]). In endometrial and ovarian cancers, TAGLN2 was downregulated in metastatic tumors compared with primary tumors ([@b17-mmr-20-05-4045]). Downregulated TAGLN2 expression has been reported to be a prognostic indicator for shorter disease-free survival in Barrett\'s adenocarcinoma ([@b15-mmr-20-05-4045]). A notable correlation was observed between reduced TAGLN2 expression and regional lymph node metastasis.

Reactive oxygen species (ROS) serve important roles in the migration and invasion of cancer cells ([@b19-mmr-20-05-4045]--[@b23-mmr-20-05-4045]). The stimulation of cell surface receptors with growth factors and integrin induces the production of ROS. The dynamic nature of actin and mitochondrial dysfunction have been associated with ROS production ([@b24-mmr-20-05-4045]). ROS act within cells to activate downstream signaling pathways, including the nuclear factor-κB (NF-κB), and signaling transducer and activator of transcription 3 pathways that promote migration and invasion ([@b25-mmr-20-05-4045]--[@b29-mmr-20-05-4045]). Peroxiredoxin 1 (PRDX1) belongs to the peroxiredoxin family of antioxidant enzymes, which serve an important role in the maintenance of intracellular ROS levels ([@b30-mmr-20-05-4045]--[@b32-mmr-20-05-4045]). The reduced expression of PRDX1 results in decreased total antioxidant capacity, inducing ROS production ([@b33-mmr-20-05-4045]). In breast cancer, PRDX1 functions as a specific sensor in redox-regulated senescence; silencing of PRDX1 increased the susceptibility for developing Ras-induced breast cancer ([@b34-mmr-20-05-4045]). Thus, the dysfunction of PRDX1 may contribute to the progression of breast cancer.

Our previous results from differential proteomics and immunohistochemical analyses revealed that TAGLN2 was downregulated in MDA-MB-231HM cells, which has a high metastatic potential ([@b7-mmr-20-05-4045]). Additionally, immunohistochemical analysis demonstrated that the expression of TAGLN2 was suppressed in lymph node-positive invasive ductal carcinoma tissues ([@b7-mmr-20-05-4045]). These findings suggested that TAGLN2 may be negatively associated with breast cancer metastasis. Nevertheless, the biological mechanism by which TAGLN2 downregulation induces the metastatic phenotype of breast cancer cells remains unknown.

In the present study, it was demonstrated that TAGLN2 knockdown promoted MDA-MB-231 cell invasion and enhanced lung metastasis *in vivo*. In addition, TAGLN2 was determined to interact with PRDX1. Knockdown of TAGLN2 resulted in reduced PRDX1 expression, elevated ROS levels, mitochondrial redistribution and the activation of the NF-κB pathway, which led to the induction of metastasis-associated genes, including C-X-C chemokine receptor 4 (CXCR4), matrix metalloproteinase (MMP)1 and MMP2. The results of the present study suggest that loss of TAGLN2 expression may promote tumor invasion via ROS and the NF-κB pathway, PRDX1 downregulation and redistribution of the mitochondria.

Materials and methods
=====================

### Cell lines and breast tumor specimens

A panel of breast cancer cell lines were obtained from the American Type Culture Collection in June 2015, including BT-549, MDA-MB-231 and MCF-7. The 293T cell line was obtained from the Cell Bank of China in 2015 and maintained in Dulbecco\'s modified Eagles medium (Gibco; Thermo Fisher Scientific, Inc.) containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.). Cell lines underwent DNA profiling of short tandem repeats in our laboratory in 2016. The cell lines were subjected to routine cell line quality examination, via morphological analysis and mycoplasma testing by HD Biosciences every 3 months until used in the present study. Frozen aliquots were stored in liquid nitrogen; cells were cultured for ≤6 months after thawing. All human breast cancers specimens were randomly obtained from patients aged 27--79 years old with pathologically confirmed stage I--III primary breast cancer with no distant metastasis; patients underwent surgery for breast cancer between March 2003 and December 2009 at the Fudan University Shanghai Cancer Center. The specimens were stored in liquid nitrogen until analysis. All specimens contained \>90% tumor cells. All patients provided written informed consent. The study complied with the Declaration of Helsinki and was approved by the Ethics Committee of the Fudan University Shanghai Cancer Center.

Breast cancer subtypes were categorized as luminal, or based on human epidermal growth factor receptor 2 (HER2)-positive and triple negative according to the available estrogen receptor, progesterone receptor and HER2 status. TNM stage and T stage were defined according to the 6th American Joint Committee on Cancer (AJCC) TNM staging system, which include the status of tumor, lymph node and metastasis ([@b35-mmr-20-05-4045]).

### Small interfering (si)RNA, plasmid construction, transfection and luciferase assays

Specific siRNAs and negative controls (scrambled siRNA) were purchased from Shanghai GenePharma Co., Ltd. Cells cultured in 6-well plates were transfected with 100 pmol/well siRNA using Hilymax Transfection Agent (Dojindo Molecular Technologies, Inc.) according to the manufacturer\'s protocols. Scrambled siRNAs comprised random sequences with no detectable effects in human cell lines. Short hairpin (sh)RNAs were obtained from the RNAi Consortium (<https://www.broadinstitute.org/scientific-community/science/projects/rnai-consortium/rnai-consortium>). pLKO-shRNA vector was purchased from Addgene, Inc. (cat. no. 30,323). Green fluorescent protein-specific shRNAs were used as unrelated negative controls. The sequences of the siRNAs, shRNA and negative controls are listed in [Table I](#tI-mmr-20-05-4045){ref-type="table"}. The vector pGL4.32 containing NF-κB transcription responsive elements (TREs) was from Promega Corporation (cat. no. E849A).

The coding DNA sequence of human TAGLN2 was cloned into the *EcoR*I/*Not*I sites of the pCDH vector (Systembio). The clone primer sequences were listed in [Table I](#tI-mmr-20-05-4045){ref-type="table"}. For the luciferase assays, 293T-pGL4.32 cells were plated in 6-well plates and transfected with 100 pmol/well of the siRNA or a negative control. The luciferase plasmid was purchased from Beyotime Institute of Biotechnology. The luciferase activity was normalized to that of *Renilla*. The Bright-Glo™ Luciferase Assay System was used to analyze luciferase activity 48 h post-transfection.

### Protein extraction and western blot analysis

Cells were lysed in SDS cell lysis buffer containing 50 mM Tris (pH 8.1) and 1% SDS, supplemented with protease inhibitors (Roche Diagnostics) for 30 min on ice. The homogenates were centrifuged at 18,000 × g for 10 min at 4°C. Supernatants were collected, and the protein concentration was determined by a Bradford\'s assay (Bio-Rad Laboratories, Inc.); 30 µg of the proteins was loaded for analysis. The proteins were separated via 10% SDS-PAGE and transferred to polyvinylidene fluoride membranes (EMD Millipore). The membranes were probed with primary antibodies against PRDX1 (1:1,000; cat. no. EPR5433; Epitomics, Abcam, Cambridge, UK), FLAG (1:500; cat. no. F7425; Sigma-Aldrich, Merck KGaA), TAGLN2 (1:1,000; cat. no. 60044-1-lg; ProteinTech Group, Inc.), IκB (1:3,000; cat. no. 66418-1-lg; ProteinTech Group, Inc.), p50 (1:200; cat. no. 15506-1-AP; ProteinTech Group, Inc.), p65 (1:1,000; cat. no 10745-1-AP; ProteinTech Group, Inc.), MMP1 (1:1,000; cat. no. 54376; Cell Signaling Technology), MMP2 (1:1,000; cat. no. 4022; Cell Signaling Technology), CXCR4 (1:1,000; cat. no. ab181020; Abcam, Cambridge, UK), Lamin B1 (1:3,000; cat. no. 12987-1-AP; ProteinTech Group, Inc.) and GAPDH (1:3,000; cat. no. 60004-1-lg; ProteinTech Group, Inc.) on the rocking table at 4°C overnight. After washing, the membranes were incubated with appropriate horseradish peroxidase-conjugated secondary antibodies at room temperature for 60 min: Goat anti-Rabbit IgG (1:3,000; SA00001-2; ProteinTech Group, Inc.), Goat anti-Mouse IgG (1:3,000; SA00001-1; ProteinTech Group, Inc.). The bands were developed via enhanced chemiluminescence (EMD Millipore). Quantity One software version 4.6.2 (Bio-Rad Laboratories, Inc.) was used to quantify protein expression.

### Immunoprecipitation

Cells were harvested and lysed in IP buffer (50 mM Tris-Cl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) supplemented with proteinase inhibitors 1 mM PMSF, 10 µg/ml aprotonin, 5 µg/ml leupeptin, 0.5 µg/ml pepstatin and 5 mM NaF on ice for 30 min, centrifuged at 12,000 × g for 15 min at 4°C and the supernatants were collected in fresh tube. For immunoprecipitation, 2 mg lysate was incubated and rotated with 20--30 µl Anti-FLAGM2 Magnetic Beads (cat. no. M8823; Sigma-Aldrich; Merck KGaA) or complex of protein A/G magnetic beads (cat. no. B23202; [Bimake.com](Bimake.com)) and primary antibody overnight at 4°C. The resulting immunoprecipitates were washed at least three times in IP buffer, before boiling with SDS sample buffer. Immunoprecipitated material was analyzed by mass spectrometry and western blotting.

### Liquid chromatography/mass spectrometry (LC/MS) and LC/MS-MS platforms for protein identification

LC-MS/MS experiments were performed on LTQ-Orbitrap hybrid mass spectrometer (Thermo Fisher Scientific, Inc.) coupled to a Shimadzu LC-20AD LC system (Shimadzu Corporation) and SIL-20AC autosampler (Shimadzu Corporation). Tryptic peptides were separated by a PICOFRIT C18 reverse-phase column (0.075×100 mm, New Objective Inc.) at a flow rate of 300 nl/min with a 110 min-gradient. Each peptide mixture was loaded in solvent A \[95% H~2~O, 5% acetonitrile (ACN), 0.1% formic acid (FA)\] and eluted by 5% solvent B (5% H~2~O, 95% ACN, 0.1% FA) for 5 min followed by a linear gradient to 45% solvent B in the next 90 min, then the column was re-equilibrated at initial condition for 15 min. The entire eluant was sprayed into the LTQ-Orbitrap mass spectrometer via a dynamic nanospray probe (Thermo Fisher Scientific, Inc.) and analyzed in positive mode. The 3 most abundant precursor ions detected in the full MS survey scan (m/z range of 400--2000, R=60,000) by Orbitrap were isolated for further MS/MS analyzing in the linear ion trap. The automatic gain control target was set to 1,000,000 and 10,000 for MS scans and MS/MS scans, respectively. Tandem mass spectra were extracted by Bioworks (version 3.3.1 SP1, Thermo Fisher Scientific, Inc.) and submitted to Human UniProtKB/Swiss-Prot database (Proteome ID: UP000005640, 20199 entries) using TurboSequest v.28 ([@b36-mmr-20-05-4045]) search engine.

### ROS detection

Cell suspensions of MDA-MB-231 and MCF-7 were obtained in PBS and flow cytometry was performed. A total of 1×10^6^ cells were stained with 2′,7′-dichlorodihydrofluorescein diacetate (DCFDA; 1 µM) at 37°C for 30 min (Thermo Fisher Scientific, Inc.) and then analyzed with a FACSCalibur™ flow cytometer (BD Biosciences). The percentage of positively-stained cells was quantified using CELLQuest™ software v5.1 (BD Biosciences).

### RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

The tissues were homogenized with Polytron PT100 (Kinematica AG). Total RNA was extracted using TRIzol^®^ (Invitrogen; Thermo Fisher Scientific, Inc.). Total RNA, isolated from cell lines or tissues, was reverse-transcribed using the ReverTra Ace^®^ qPCR RT Kit (Toyobo Life Science). RT was conducted for 15 min at 42°C followed by 5 min at 98°C. The mRNA expression levels were quantified by qPCR using the SYBR^®^ Green Real-time PCR Master Mix (Toyobo Life Science). qPCR was performed using an Applied Biosystems 7900HT real-time PCR system, and data were collected and analyzed using ABI SDS version 2.3. The thermocycling conditions were: 95°C for 30 sec followed by 40 cycles at 95°C for 5 sec and 65°C for 30 sec. The mRNA expression levels of GAPDH were used as the internal control for gene-specific mRNA analysis. The normalized expression of each sample was designated as the quantification cycle (Cq) and obtained by dividing the Cq value by the Cq value of GAPDH of the same sample. The relative amount of mRNA in each sample was calculated using the comparative Cq method ([@b37-mmr-20-05-4045]). The results are presented as the fold change of expression in cells or cancer tissues. The sequences of primers were listed in [Table II](#tII-mmr-20-05-4045){ref-type="table"}.

### Invasion assay

The invasive potential of cells was determined by plating 40,000 cells in the upper chamber of Matrigel (BD Biosciences)-coated Transwell invasion chambers according to the manufacturer\'s instructions. The cells were seeded in DMEM without growth factors; DMEM with 10% FBS was added to the lower chamber. The cells were incubated in 37°C for 24--48 h. The invasive cells were fixed in 95% ethanol for 20 min, and stained in hematoxylin for 2 min followed by eosin staining for 1 min in room temperature. The invasive cells were imaged under a light microscope (magnification, ×10) and counted using ImageJ 1.50i software (National Institutes of Health); 5 fields per view were analyzed.

### Migration assay

Migration assay was conducted with Transparent PET Membrane 24 well 8.0 µm migration insert (Falcon; Corning Inc.) by seeding 36,000 cells into the top chamber in DMEM without growth factors and adding DMEM with 10% FBS to the bottom chamber. The cells were incubated at 37°C for 6 h. Cells were stained with 0.1% Crystal Violet Staining Solution for 30 min at room temperature and imaged under a light microscope (magnification, ×10). The number of migrated cells was counted with ImageJ 1.50i software (National Institutes of Health) and 5 fields per view were analyzed. SN50, an NF-κB inhibitor, from MedChemExpress (cat. no. HY-P0151) was dissolved in dimethyl sulfoxide (DMSO). MDA-MB-231 cells transfected with scramble or shTAGLN2 were treated with 18 µM SN50 or DMSO for 24 h before migration assay.

### Mitochondrial and F-actin staining

Cells were cultured on coverslips and treated as aforementioned. Cells were fixed in 4% paraformaldehyde for 10 min at room temperature prior to permeabilization in PBS containing 0.1% Triton X-100 for 2 min. MitoTracker Red CMXRos (Thermo Fisher Scientific, Inc.) was used for mitochondrial staining at 37°C for 30 min. Phalloidin-fluorescein isothiocyanate (Sigma-Aldrich; Merck KGaA) was used for F-actin staining at 37°C for 30 min. Cells were rinsed 3 times with PBS and incubated with DAPI (1 µg/ml; cat. no. 9542; Sigma-Aldrich; Merck KGaA) at 37°C for 30 min. Slides were analyzed by Leica DMi6000 B inverted microscope (Leica Microsystems, Inc.) according to manufacturer\'s instruction and 3 fields per view were analyzed.

### In vivo metastasis assay

Female athymic mice (Shanghai SLAC Laboratory Animal Co., Ltd.), 4--6 weeks of age, 18--22 g in weight were employed in the present study. A total of 5×10^6^ MDA-MB-231 cells stably expressing scramble shRNA or shRNA-TAGLN2 were intravenously injected into mice via the tail vein (6 mice per group). At 6 weeks post-injection, mice in each group were sacrificed and the lungs were dissected for the analysis of metastasis.

In addition, 1×10^7^ MDA-MB-231HM cells transfected with TAGLN2 or control vectors were injected into the mammary fat pad of mice (6 mice per group). The growth of tumors was monitored twice per week for \~2 weeks, when tumors were 1 cm^3^, the primary tumor was surgically removed under anesthesia. After 4 weeks, mice were sacrificed under anesthesia and the lungs were collected, fixed in 10% phosphate-buffered formalin solution for 12 h at room temperature and embedded in paraffin. Sections of the lungs were subjected to H&E staining for 3 min at room temperature; three slides per lung section were imaged under a light microscope (magnifications, ×10 and 20). The presence of metastatic nodes in the lung were determined by two independent pathologists, who were blinded to the experimental conditions.

### Statistical analysis

The results of at least three experiments are expressed as the mean ± standard deviation. One-way ANOVA was used for comparisons between multiple groups and post hoc multiple comparisons were performed using Student-Newman-Keuls test. A Student\'s t-test was used for the test and control samples, respectively. A Fisher\'s exact test and a χ^2^ test were used to analyze categorical patient variables. P\<0.05 was considered to indicate a statistically significant difference. Statistical calculations were performed using STATA software version 14.0 (StataCorp LLC); statistical analysis of the clinicopathological factors was performed with GraphPad Prism 6.0 software (GraphPad Software, Inc.) and SPSS Software version 17.0 (SPSS, Inc.).

Results
=======

### TAGLN2 is a suppressor of metastasis in human breast cancer

TAGLN2 was downregulated in MDA-MB-231HM cells, which are a highly metastatic variant of the parental MDA-MB-231 cell line ([@b7-mmr-20-05-4045]). To further understand the link between TAGLN2 and breast cancer metastasis, we analyzed the expression of TAGLN2 in 158 primary tumor samples from patients with breast cancer at the Fudan University Shanghai Cancer Center. Associations between TAGLN2 expression and the clinicopathological parameters of the breast cancer patients were summarized in [Table III](#tIII-mmr-20-05-4045){ref-type="table"}. The results revealed that no significant association was observed between TAGLN2 expression and age, histological type, tumor size, stage, and ER, PR or HER2 status. However, TAGLN2 expression was upregulated by \>4.9-fold in the tumor specimens from lymph node-negative patients compared with that of lymph node-positive patients. Additionally, TAGLN2 expression was upregulated by 11.4-fold in the primary tumors of metastasis-negative patients compared with those exhibiting metastasis ([Table III](#tIII-mmr-20-05-4045){ref-type="table"}). These findings suggested that low levels of TAGLN2 were associated with the metastatic behavior in breast cancer.

### Loss of TAGLN2 is associated with an aggressive tumor phenotype

The present study reported that downregulation of TAGLN2 was associated with breast cancer metastasis; thus, it was proposed that knockdown of TAGLN2 in breast cancer cells could promote cell invasion and metastasis. We established cell lines exhibiting stable TAGLN2 silencing from the parental MDA-MB-231 and BT-549 cell lines using the pLKO-shRNA vector ([Fig. 1A](#f1-mmr-20-05-4045){ref-type="fig"}). The following experiments were conducted with shRNA252 in MDA-MB-231 and shRNA377 in BT-549 cells. The results indicated that knockdown of TAGLN2 significantly promoted the invasive abilities of MDA-MB-231 and BT-549 cells compared with the corresponding control ([Fig. 1B and C](#f1-mmr-20-05-4045){ref-type="fig"}).

To further investigate the role of TAGLN2 in tumor metastasis *in vivo*, MDA-MB-231 cells that were stably depleted of TAGLN2 were injected into nude mice via the lateral tail vein. Histological analysis of the mice lungs revealed that knockdown of TAGLN2 could promote lung metastasis. The numbers and size of the lung nodules were significantly increased in the MDA-MB-231-shTAGLN2 group compared with that of the MDA-MB-231-scramble group ([Fig. 1D](#f1-mmr-20-05-4045){ref-type="fig"}). Collectively, the results of the present study suggest that TAGLN2 could be a negative regulator of breast cancer metastasis.

### TAGLN2 directly interacts with PRDX1 and loss of TAGLN2 promotes ROS production

TAGLN2 has been reported as an actin-binding protein, and it may serve a role in regulating the cytoskeleton, which cooperatively functions in a variety of cellular processes and regulates the distribution of mitochondria ([@b38-mmr-20-05-4045]). The present study revealed that mitochondria were sparsely distributed in TAGLN2-knockdown cells; however, no alterations in the morphology of F-actin were detected ([Fig. 2A](#f2-mmr-20-05-4045){ref-type="fig"}). To investigate the molecular mechanisms of TAGLN2 in breast cancer metastasis, we examined the proteins that interact with TAGLN2. TAGLN2 protein was immunoprecipitated from MDA-MB-231 lysates; the co-immunoprecipitated proteins were analyzed by MS, and the identified peptides were matched to protein databases to identify the parent proteins ([Fig. 2B](#f2-mmr-20-05-4045){ref-type="fig"}; [Table IV](#tIV-mmr-20-05-4045){ref-type="table"}). FLAG-tagged TAGLN2 vector was transfected in MDA-MB-231 cells and TAGLN2 was overexpressed; PRDX1 was determined to interact with TAGLN2 by immunoprecipitation analysis ([Fig. 2C](#f2-mmr-20-05-4045){ref-type="fig"}). In addition, the expression of PRDX1 was reduced in response to TAGLN2 silencing ([Fig. 2D](#f2-mmr-20-05-4045){ref-type="fig"}). We also downregulated TAGLN2 in MCF-7 cells ([Fig. 2E](#f2-mmr-20-05-4045){ref-type="fig"}).

Mitochondria are a major cellular source of ROS ([@b39-mmr-20-05-4045]). PRDX1 is also involved in cellular ROS production ([@b30-mmr-20-05-4045]). Flow cytometry was conducted to measure the levels of intracellular ROS following TAGLN2 downregulation ([Fig. 2F](#f2-mmr-20-05-4045){ref-type="fig"}). TAGLN2-depleted MDA-MB-231 and MCF-7 cells were stained with DCFDA; ROS production was then analyzed by flow cytometry ([@b40-mmr-20-05-4045]). ROS levels were significantly increased by 21 and 12% in MDA-MB-231 and MCF-7 cells following TAGLN2 knockdown, respectively, compared with the corresponding controls ([Fig. 2F and G](#f2-mmr-20-05-4045){ref-type="fig"}). These results suggest that downregulation of TAGLN2 induced the rearrangement of the mitochondria and the abnormal expression of PRDX1, by which several mechanisms underlying ROS production were induced.

### Downregulation of TAGLN2 activates the NF-κB pathway in breast cancer cell lines

ROS have been reported to promote cellular migration and invasion by activating downstream signaling, including the NF-κB signaling pathway ([@b41-mmr-20-05-4045]). Thus, we proposed that TAGLN2 knockdown could induce ROS production, activating the NF-κB signaling pathway. Therefore, a luciferase-reporter system was generated to monitor NF-κB activation. The luciferase activity within the reporter system increased in a dose-dependent manner following treatment with various concentrations of tumor necrosis factor-α ([Fig. S1A](#SD1-mmr-20-05-4045){ref-type="supplementary-material"}). Furthermore, in cells transfected with the luciferase reporter vector and NF-κB transcription responsive elements (TREs) were treated with siRNA-TAGLN2 or scramble siRNA. As expected, cells with NF-κB TREs exhibited a 2.2-fold increase in luciferase expression in response to TAGLN2 knockdown ([Fig. 3A](#f3-mmr-20-05-4045){ref-type="fig"}). Western blot analysis was performed to examine NF-κB pathway activation. The results revealed that the expression levels of p50 and p65 were upregulated in MDA-MB-231 and MCF-7 cells transfected with shTAGLN2. Of note, IκB expression was suppressed following downregulation of TAGLN2 ([Fig. 3B](#f3-mmr-20-05-4045){ref-type="fig"}). In addition, the nuclear localization of p65 was analyzed, and served as a marker of activated NF-κB ([Fig. S1B](#SD1-mmr-20-05-4045){ref-type="supplementary-material"}). In 10 human breast cancer cell lines, TAGLN2 expression was negatively correlated with the nuclear expression of p65 ([Fig. S1C](#SD1-mmr-20-05-4045){ref-type="supplementary-material"}). Similar trends in the expression of p50 and p100 were observed in ZR-75-1, MCF-7, T47D, MDA-MB-231 and MDA-MB-468 cells ([Fig. S1B and C](#SD1-mmr-20-05-4045){ref-type="supplementary-material"}). To further investigate the association between TAGLN2 and NF-κB activation, MDA-MB-231 cells transfected with scramble or shTAGLN2 were treated with 18 µM SN50, an NF-κB inhibitor, for 24 h. Following inhibition of the NF-κB signaling pathway, the pro-migratory effects of TAGLN2 downregulation were reversed ([Fig. 3C](#f3-mmr-20-05-4045){ref-type="fig"}). These results supported the findings of the luciferase reporter assay and revealed that knockdown of TAGLN2 promoted the activation of NF-κB pathway in breast cancer cells.

### Downregulation of TAGLN2 promotes microenvironment-associated gene expression in breast cancer cells

The present study reported that knockdown of TAGLN2 promoted the formation of lung metastases by breast cancer cells. To determine the genes that were associated with the metastatic phenotype, RT-qPCR analysis of the microenvironment-associated genes was conducted, including genes involved in the immune and inflammatory responses, such as cell adhesion molecules, chemokines and MMPs ([@b42-mmr-20-05-4045]). The results indicated that interleukin-6, C-X-C motif chemokine ligand 1, CXCR4, MMP1 and MMP2 were significantly upregulated in MDA-MB-231 cells transfected with shTAGLN2 compared with the control ([Fig. 4A](#f4-mmr-20-05-4045){ref-type="fig"}). MMP1, MMP2 and MMP9 were significantly upregulated in MCF-7 cells following TAGLN2 knockdown compared with the control ([Fig. 4B](#f4-mmr-20-05-4045){ref-type="fig"}). Western blot analysis was performed to examine the expression of the metastasis-associated genes. In accordance with results of the RT-qPCR analysis, MMP1 and MMP2 were upregulated following downregulation of TAGLN2 in MDA-MB-231 and MCF-7 cells ([Fig. 4C](#f4-mmr-20-05-4045){ref-type="fig"}). Furthermore, MDA-MB-231 scramble and shTAGLN2-transfected cells were treated with SN50 to inhibit the NF-κB signaling pathway. The results demonstrated that the expression levels of MMP1 and MMP2 were downregulated in response to SN50 treatment compared with shTAGLN2 transfection alone ([Fig. 4D](#f4-mmr-20-05-4045){ref-type="fig"}). These findings suggested that downregulation of TAGLN2 promoted the expression of microenvironment-associated genes in breast cancer cells.

### Overexpression of TAGLN2 suppresses in vivo breast cancer cell lung metastasis in a mouse model

To further examine the effects of TAGLN2 on host-tumor interactions in a mouse model, MDA-MB-231HM cells stably expressing the control or TAGLN2 overexpression vectors were injected into the mammary fat pad of athymic mice. Compared with the control group, the orthotropic transplantation of pCDH-CMV-TAGLN2-transfected MDA-MB-231HM cells resulted in fewer metastatic tubes in the lungs *in vivo* ([Fig. 5A](#f5-mmr-20-05-4045){ref-type="fig"}). Statistical analysis revealed a significant decrease in the number of metastatic tubes derived from the TAGLN2-overexpressing MDA-MB-231HM cells than of the control cells ([Fig. 5B](#f5-mmr-20-05-4045){ref-type="fig"}). Collectively, the findings of the present study suggested that overexpression of TAGLN2 suppressed breast cancer cell metastasis in a mouse model.

Discussion
==========

In the present study, loss of TAGLN2 was reported to promote breast cancer cell invasion and metastasis by increasing intracellular ROS levels and activation of the NF-κB signaling pathway. The effects of TAGLN2 may be mediated by its interaction with PRDX1 and the redistribution of the mitochondria ([Fig. 6](#f6-mmr-20-05-4045){ref-type="fig"}).

TAGLN, which contains a calponin-like domain, functions as a tumor suppressor ([@b43-mmr-20-05-4045],[@b44-mmr-20-05-4045]). Loss of TAGLN has been associated with the progression, differentiation and metastasis of colon cancer ([@b18-mmr-20-05-4045]). TAGLN also inhibits tumor cell invasion via MMP9 suppression ([@b45-mmr-20-05-4045]). Similar to TAGLN, TAGLN2 also belongs to the calponin family of proteins and may act as a tumor suppressor ([@b14-mmr-20-05-4045]). Discrepancies in the functions of TAGLN2 have been reported previously. Upregulated TAGLN2 expression was associated with the development of gliomas ([@b46-mmr-20-05-4045]), uterine cervical squamous carcinoma ([@b47-mmr-20-05-4045]) and esophageal squamous carcinoma ([@b48-mmr-20-05-4045]). On the contrary, Yoshida *et al* ([@b17-mmr-20-05-4045]) reported that TAGLN2 was downregulated in metastatic tumors of the brain than in primary endometrial and ovarian cancers, suggesting TAGLN2 as a suppressor of metastasis. Zheng *et al* ([@b49-mmr-20-05-4045]) revealed that knockdown of TAGLN2 improved the sensitivity of paclitaxel-resistant MCF-7 cells to paclitaxel treatment, and suppressed cellular migration and invasion; however, the mechanisms underlying the functions of TAGLN2 remain poorly understood. The results of the present study indicated that TAGLN2 was downregulated in metastasis-positive patients with breast cancer and MDA-MB-231HM cells. Therefore, TAGLN2 may be negatively associated with breast cancer metastasis. Depleted TAGLN2 expression by RNA interference could enhance the metastatic properties including invasion ability *in vitro* and promotion of lung metastasis *in vivo* of breast cancer cells. Xenograft models indicated that TAGLN2 inhibited the metastasis of breast cancer cells to the lungs. The findings of the present study suggest that TAGLN2 may serve as a suppressor of breast cancer metastasis.

Using LC/MS, we identified several TAGLN2-interacting proteins, including oxidation-regulation protein PRDX1, which has been reported to reduce the effects of ROS and regulate ROS-dependent signaling pathways ([@b32-mmr-20-05-4045],[@b50-mmr-20-05-4045]). Additionally, downregulation of TAGLN2 was proposed to reduce the expression of PRDX1 in the present study, which may partially contribute to increases in ROS levels. Alternatively, TAGLN2 may regulate ROS levels through the redistribution of the mitochondria. The dynamic actin cytoskeleton and specific actin-binding proteins are required for the regular and ordered transport of the mitochondria ([@b51-mmr-20-05-4045]--[@b53-mmr-20-05-4045]). The actin cytoskeleton is a key component involved in the regulation of intracellular ROS production ([@b54-mmr-20-05-4045]--[@b55-mmr-20-05-4045]). TAGLN2 associated with the cytoskeleton may serve as a sensor of environmental stress and participate in the modulation of certain signaling pathways. Consistent with this notion, TAGLN2 depletion may result in the redistribution of mitochondria and elevated ROS levels; increased ROS production in response to TAGLN2 depletion suggests that TAGLN2 may function as a suppressor of metastasis via signaling pathways mediated by ROS. Activation of the NF-κB pathway induces the expression of microenvironment-associated genes that promote the metastasis of breast cancer cells ([@b56-mmr-20-05-4045]). The findings of the present study may provide insight as to how cytoskeletal proteins may actively affect cancer metastasis. Therefore, inducing the expression of TAGLN2 could serve as a therapeutic strategy to suppress the expression of microenvironment-associated genes in various types of cancer.

Colonization is a critical, rate-limiting step of the metastatic cascade ([@b57-mmr-20-05-4045]). The communication between tumor cells and surrounding cells serves an important role in colonization ([@b58-mmr-20-05-4045]--[@b59-mmr-20-05-4045]). CXCR4 is an important molecule involved in the spread and progression of breast cancer. Increased CXCR4 expression serves as an indicator of poor prognosis in patients with breast cancer. MMPs are crucial for the development of healthy tissue architecture, and serve critical roles in numerous physiological and pathological processes. Similar to CXCR4, MMPs also play key roles in tumor invasion and the induction of metastasis. The expression of MMPs has also been associated with the poor prognosis of patients with breast cancer ([@b60-mmr-20-05-4045]). Our findings demonstrated that loss of TAGLN2 induces CXCR4, MMP1 and MMP2 expression, and promotes cancer metastasis. Additionally, TAGLN2 expression was associated with lymph node metastasis and distant metastasis, which are important prognostic factors in breast cancer patients. However, the clinical significance of TAGLN2 requires further investigation, in particular the outcomes of breast cancer patients of the same age, gender, ER/PR/HER-2 status, receiving similar treatment, and varying expression levels of TAGLN2, which we aim to study in the future. In addition, our *in vivo* analysis of lung metastasis for comparing MDA-MB-231 cells with TAGLN2 low/high-expression with the control cells may provide further insight into the role of TAGLN2 in the present study.

In summary, we identified TAGLN2 as a tumor suppressor associated with breast cancer metastasis, in which its effects could be mediated by redox signaling, and may be a novel role for TAGLN2 in the regulation of cancer cell metastasis. Therefore, TAGLN2 may be considered as a critical regulator of the ROS/NF-κB pathway in breast cancer.
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:   transgelin 2

PRDX1

:   peroxiredoxin 1
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:   reactive oxygen species
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:   estrogen receptor

PR

:   progesterone receptor
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![Loss of TAGLN2 promotes breast cancer cell invasion *in vitro* and metastasis *in vivo*. (A) Immunoblotting of TAGLN2 expression in MDA-MB-231 and BT549 cells transfected with TAGLN2 shRNA252, shRNA377, shRNA586 and scramble RNA. Data shown were representative of three independent experiments. Knockdown of TAGLN2 significantly promoted the invasion of (B) MDA-MB-231 and (C) BT-549 cell lines following transfection with pLKO.1-shRNA-TAGLN2 compared with cells transfected with scramble shRNA. Data were representative of three independent experiments. (D) Representative H&E-stained sections of the lung tissues isolated from mice injected with MDA-MB-231 cells transfected with shRNA-TAGLN2 or shRNA-scramble via the lateral tail vein. The arrowhead indicated tumor formation in the lung. The number of metastatic nodules in the lung were counted and analyzed; n=6 mice per group. Scale bar, 200 µm. \*P\<0.05 vs. scramble. shRNA, short hairpin RNA; TAGLN2, transgelin 2.](MMR-20-05-4045-g00){#f1-mmr-20-05-4045}

![TAGLN2 promotes ROS production by interacting with PRDX1 and altering actin dynamics. (A) MDA-MB-231-scramble (left panel) and MDA-MB-231-shRNA-TAGLN2 (right panel) cells were stained for F-actin (green), mitochondria (red) and the nucleus (blue). Scale bar, 5 µm. (B) Liquid chromatography-MS analysis followed by MS/MS of immunoprecipitated FLAG-TAGLN2 from MDA-MB-231 cells revealed the interaction between PRDX1 and TAGLN2 in MDA-MB-231 cells. (C) Overexpression of TAGLN2, and co-immunoprecipitation of PRDX1 with TAGLN2. MDA-MB-231 cells were transfected with FLAG-tagged TAGLN2 and subjected to immunoprecipitation with anti-FLAG antibody followed by immunoblotting with antibodies. (D) Representative immunoblots of PRDX1 with TAGLN2 expression following TAGLN2 depletion in MDA-MB-231 cells. (E) The mRNA expression levels of TAGLN2 with TAGLN2 siRNA in MDA-MB-231 and MCF-7 cells. (F) Levels of ROS in MDA-MB-231 and MCF-7 cells treated with siRNA TAGLN2 as determined by flow cytometry, and presented as the fluorescence intensity of 2′,7′-dichlorodihydrofluorescein diacetate. (G) The data were representative of five independent experiments. \*P\<0.05 and \*\*\*\*P\<0.00005 vs. control. MS, mass spectrometry; PRDX1, peroxiredoxin 1; ROS, reactive oxygen species; shRNA, short hairpin RNA; siRNA, small interfering RNA; TAGLN2, transgelin 2.](MMR-20-05-4045-g01){#f2-mmr-20-05-4045}

![Loss of TAGLN2 expression induces NF-κB activation. (A) Luciferase activity of an NF-κB-luciferase reporter plasmid in TAGLN2-overexpressing 293T cells was measured 48 h after stimulation with siRNA-TAGLN2 or scramble siRNA; luciferase activity was normalized to that of *Renilla*. Data were representative of three independent experiments. (B) Immunoblotting of IκB, p50, p65/RelA and TAGLN2 expression in MDA-MB-231 and MCF-7 cells transfected with pLKO.1-shRNA-TAGLN2 and pLKO.1-shRNA-scramble. The results of western blotting were representative of three independent experiments. (C) Cell migration was promoted in MDA-MB-231 cells transfected with pLKO.1-shRNA-TAGLN2 compared with cells treated with scramble shRNA. Treatment with 18 µM SN50 for 24 h reversed the effects of TAGLN2 downregulation on cell invasion. Data are representative of three independent experiments. \*P\<0.05 vs. scramble or as indicated. DMSO, dimethyl sulfoxide; NF-κB, nuclear factor-κB; shRNA, short hairpin RNA; siRNA, small interfering RNA; TAGLN2, transgelin 2.](MMR-20-05-4045-g02){#f3-mmr-20-05-4045}

![Analysis of metastasis-associated genes in TAGLN2-knockdown cancer cells. (A) RT-qPCR analysis of ICAM1, VCAM1, IL6, CXCL1, CCL2, CXCR4, CCR4, MMP1, MMP2, and MMP9 mRNA expression in MDA-MB-231 cells treated with scramble or shTAGLN2; results are presented relative to β-actin expression. Data shown was representative of three independent experiments. (B) RT-qPCR analysis of ICAM1, VCAM1, IL6, CXCL1, CCL2, CXCR4, CCR4, MMP1, MMP2 and MMP9 mRNA expression in MCF-7 cells treated with shControl or shTAGLN2; results are presented as relative to β-actin expression. Data are representative of three independent experiments. (C) Immunoblotting of CXCR4, MMP1 and MMP2 expression in MDA-MB-231 and MCF-7 cells treated with scramble or shTAGLN2. Western blots were representative of three independent experiments. (D) RT-qPCR analysis of MMP1 and MMP2 in MDA-MB-231 cells transfected with scramble or shTAGLN2 under treatment of DMSO or SN50 (18 µM) for 24 h. Data are representative of three independent experiments. \*P\<0.05 vs. scramble or as indicated. CCL2, C-C motif chemokine ligand 2; CXCL1, C-X-C motif chemokine ligand 1; CCR4, C-C chemokine receptor type 4; CXCR4, including C-X-C chemokine receptor 4; DMSO, dimethyl sulfoxide; ICAM1, intercellular adhesion molecule 1; IL6, interleukin-6; MMP, matrix metalloproteinase; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; shRNA, short hairpin RNA; TAGLN2, transgelin 2; VCAM1, vascular cell adhesion protein 1.](MMR-20-05-4045-g03){#f4-mmr-20-05-4045}

![Overexpression of TAGLN2 suppresses *in vivo* lung metastasis in a mouse model. (A) Hematoxylin-eosin staining of lung tissues from mice injected with MDA-MB-231HM cells transfected with pCDH-CMV-TAGLN2 or control vector. The red arrows the lung tubes formed. Scale bar, 200 µm. (B) Number of metastatic lung tubes in mice injected with MDA-MB-231HM cells transfected with pCDH-CMV-TAGLN2 or control vector. n=6 mice per group. \*P\<0.05. TAGLN2, transgelin 2.](MMR-20-05-4045-g04){#f5-mmr-20-05-4045}

![Schematic representation of the effects of TAGLN2 on breast cancer metastasis. CXCR4, including C-X-C chemokine receptor 4; MMP, matrix metalloproteinase; NF-κB, nuclear factor-κB; P, phosphorylated; PRDX1, peroxiredoxin 1; ROS, reactive oxygen species; TAGLN2, transgelin 2.](MMR-20-05-4045-g05){#f6-mmr-20-05-4045}

###### 

Sequences of primers, siRNA and shRNAs.

  Purposes                   Sequence type   Sequence (5′-3′)
  -------------------------- --------------- -------------------------------------------------------------
  TAGLN2 clone primer        Sense           GTCAGTGCGCTGCTCTCC
                             Antisense       CCCTGACAGAAAGGAGCTTG
  TAGLN2 FLAG clone primer   Sense           GCGAAGCTTGCCAACAGGGGACCTGC
                             Antisense       AGAATTCTCAGAGGATCTGGCGTGGC
  TAGLN2 shRNA 586           Top             CCGGGAACGTGATCGGGTTACAGATCTCGAGATCTGTAACCCGATCACGTTCTTTTTTG
                             Bottom          aattCAAAAAAGAACGTGATCGGGTTACAGATCTCGAGATCTGTAACCCGATCACGTTC
  TAGLN2 shRNA 377           Top             CCGGCGCTATGGCATTAACACCACTCTCGAGAGTGGTGTTAATGCCATAGCGTTTTTTG
                             Bottom          aattCAAAAAACGCTATGGCATTAACACCACTCTCGAGAGTGGTGTTAATGCCATAGCG
  TAGLN2 shRNA 252           Top             CCGGCGGTGCTATGTGAGCTCATTACTCGAGTAATGAGCTCACATAGCACCGTTTTTTG
                             Bottom          aattCAAAAAACGGTGCTATGTGAGCTCATTACTCGAGTAATGAGCTCACATAGCACCG
  siRNA TAGLN2 252           Target          CGACCAATAGCTCAGATCCTT
  siRNA TAGLN2 377           Target          CAGGTGATACTATCAACCAAA
  siRNA negative control                     GUGGAUAUUGUUGCCAUCA

shRNA, short hairpin RNA; siRNA, small interfering RNA; TAGLN2, transgelin 2. The lowercase letters represent restriction endonuclease site of EcoRI.

###### 

List of primers employed reverse transcription-quantitative polymerase chain reaction.

  Gene      Sequence type   Sequence (5′-3′)
  --------- --------------- -------------------------
  TAGLN2    Sense           ACCCAGTGCCGAAAGGATG
            Antisense       TCAGTGGTGTTAATGCCATAGC
  VCAM1     Sense           GCTGCTCAGATTGGAGACTCA
            Antisense       CGCTCAGAGGGCTGTCTATC
  ICAM1     Sense           ATGCCCAGACATCTGTGTCC
            Antisense       GGGGTCTCTATGCCCAACAA
  CX3CL1    Sense           ACCACGGTGTGACGAAATG
            Antisense       CTCCAAGATGATTGCGCGTTT
  CCL2      Sense           CAGCCAGATGCAATCAATGCC
            Antisense       TGGAATCCTGAACCCACTTCT
  CCR4      Sense           ATGAACCCCACGGATATAGCA
            Antisense       CACCACAGAATTTCCAAGCAGA
  CXCR4     Sense           TACACCGAGGAAATGGGCTCA
            Antisense       AGATGATGGAGTAGATGGTGGG
  IL6       Sense           AACCTGAACCTTCCAAAGATGG
            Antisense       TCTGGCTTGTTCCTCACTACT
  MMP1      Sense           ACACATCTGACCTACAGGATTGA
            Antisense       GTGTGACATTACTCCAGAGTTGG
  MMP2      Sense           CCCACTGCGGTTTTCTCGAAT
            Antisense       CAAAGGGGTATCCATCGCCAT
  MMP9      Sense           TGTACCGCTATGGTTACACTCG
            Antisense       GGCAGGGACAGTTGCTTCT
  β-actin   Sense           TGACGTGGACATCCGCAAAG
            Antisense       CTGGAAGGTGGACAGCGAGG

CCL2, chemokine ligand 2; CCR4, C-C motif chemokine receptor 4; CX3CL1, C-X3-C motif chemokine ligand 1; CXCR4, C-XC chemokine receptor type 4; ICAM1, intercellular adhesion molecule 1; IL, interleukin; MMP, matrix metalloproteinase; TAGLN2, transgelin 2; VCAM1, vascular cell adhesion protein 1.

###### 

Association between TAGLN2 expression and clinicopathologic parameters in breast cancer.

  Clinicopathological parameters                                       Number of cases   Median expression of TAGLN2 (normalized Cq)^[a](#tfn3-mmr-20-05-4045){ref-type="table-fn"}^   P-value
  -------------------------------------------------------------------- ----------------- --------------------------------------------------------------------------------------------- ---------
  Age, years                                                                                                                                                                           0.676
    ≤40                                                                26                10.158±3.124                                                                                  
    \>40                                                               132               9.972±3.962                                                                                   
  Histological type                                                                                                                                                                    0.887
    DCIS                                                               20                10.67±3.951                                                                                   
    IDC                                                                138               9.973±3.542                                                                                   
  TNM stage                                                                                                                                                                            0.523
    I+II                                                               146               9.986±3.734                                                                                   
    III                                                                12                9.831±3.894                                                                                   
  Lymph node status                                                                                                                                                                    \<0.001
    Negative                                                           76                8.780±3.751                                                                                   
    Positive                                                           82                11.081±3.926                                                                                  
  Tumor size                                                                                                                                                                           0.322
    T1 + T2                                                            132               9.888±3.619                                                                                   
    T3 + T4                                                            26                10.412±3.820                                                                                  
  ER                                                                                                                                                                                   0.713
    Negative                                                           61                9.875±3.756                                                                                   
    Positive                                                           97                10.037±3.852                                                                                  
  PR                                                                                                                                                                                   0.923
    Negative                                                           66                9.891±3.762                                                                                   
    Positive                                                           92                10.034±3.834                                                                                  
  HER2                                                                                                                                                                                 0.874
    Negative                                                           125               9.806±3.782                                                                                   
    Positive                                                           33                10.613±3.696                                                                                  
  Distant metastasis^[b](#tfn4-mmr-20-05-4045){ref-type="table-fn"}^                                                                                                                   \<0.001
    Absent                                                             117               9.064±3.715                                                                                   
    Present                                                            41                12.573±3.786                                                                                  
  All cases                                                            158               9.974±3.770                                                                                   

Normalized Cq=Cq TAGLN2-Cq GAPDH.

Metastasis defined as distant metastasis after surgery. DCIS, ductal carcinoma *in situ*; IDC, invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNM, tumor-node-metastasis; Based on Pearson χ^2^ test, for which P-vales are based on Fisher\'s exact test.

###### 

Parent proteins.

  Protein name (Uniprot ID)          MS-identified sequence   MH+       z   m/z
  ---------------------------------- ------------------------ --------- --- ---------
  Transgelin-2 (TAGL2)               NFSDNQLQEGK              1279.59   2   640.30
  (P37802)                           TLM\*NLGGLAVAR           1231.68   2   616.35
                                     TLMNLGGLAVAR             1215.69   2   608.35
                                     QM\*EQISQFLQAAER         1694.82   2   847.91
                                     DDGLFSGDPNWFPK           1594.72   2   797.86
                                     QMEQISQFLQAAER           1678.82   2   839.91
                                     YGINTTDIFQTVDLWEGK       2100.03   2   1050.52
  Peroxiredoxin-1 (PRDX1) (Q06830)   ATAVMPDGQFK              1164.57   2   582.79
                                     QITVNDLPVGR              1211.67   2   606.34
                                     QGGLGPM\*NIPLVSDPK       1638.85   2   819.93
                                     QGGLGPMNIPLVSDPK         1622.86   2   811.93
                                     GLFIIDDKGILR             1359.80   2   680.40

M\* represents the oxidized Met residue.

[^1]: Contributed equally
